Article Figures & Data
Figures
- Figure 1.
The hierarchical cluster analysis of patients with anti-NXP2 antibody–positive myositis. The dendrogram was generated using Euclidean distance and the Ward agglomerative method. The bold vertical line indicates the height of fusion into the proposed clusters, and the X-axis indicates the individuals (n = 70) at the bottom of the dendrogram. anti-NXP2: antinuclear matrix protein 2.
- Figure 2.
The comparison of survival time between cluster 1 and cluster 2. Cum: cumulative; m: months.
- Figure 3.
The classification and regression trees of each cluster. The regression tree model was used to identify the class within which a target variable would presumably fall. Using classification and regression trees, age of disease onset was identified as a predictor that positioned patients into different clusters. The main clinical characteristics of the different clusters are shown in the lower boxes. anti-NXP2: antinuclear matrix protein 2.
Tables
Cluster 1, n = 37 Cluster 2, n = 33 P Age at onset, yrs, mean (SD) 30.41 (7.83) 52.03 (9.76) < 0.001** Age at onset, yrs 18-30 20 (54) 0 (0) < 0.001** 31-40 14 (38) 3 (9) 0.005** 41-50 3 (8) 11 (33) 0.008 51-60 0 (0) 13 (39) < 0.001** 61-70 0 (0) 4 (12) 0.045 > 70 0 (0) 2 (6) 0.22 Sex 0.40 Male 16 (43) 11 (33) Female 21 (57) 22 (67) Duration from onset to diagnosis, months, median (IQR) 2.0 (1.5-5.0) 2.0 (1.0-3.5) 0.16 Muscle weakness 0.27 Any muscle weakness 37 (100) 33 (100) Severe muscle weakness 10 (27) 13 (39) Myalgia 29 (78) 25 (76) 0.79 Rash All rash types 29 (78) 30 (91) 0.15 Heliotrope rash 23 (62) 22 (67) 0.70 V sign 9 (24) 22 (67) < 0.001** Shawl sign 4 (11) 17 (52) < 0.001** Holster sign 4 (11) 4 (11) 1.000 Mechanic’s hands 3 (8) 7 (19) 0.22 Gottron sign and papules 8 (22) 12 (32) 0.17 Cutaneous ulcer 3 (8) 6 (16) 0.29 Subcutaneous calcification 8 (22) 1 (3) 0.03* Subcutaneous edema 12 (33) 14 (42) 0.39 Arthritis 2 (5) 3 (9) 0.66 Interstitial lung disease 6 (16) 15 (45) 0.008** Dysphagia 23 (62) 20 (61) 0.89 WBCs, mean (SD)a All WBCs, × 109/L 8.12 (3.91) 9.23 (4.33) 0.26 Neutrophils, × 109/L 6.24 (3.81) 7.61 (4.06) 0.15 Lymphocytes All lymphocytes, × 109/L 1.23 (0.67) 0.97 (0.36) 0.04* CD3, cells/μL 850.65 (515.96) 741.35 (365.80) 0.33 CD4, cells/μL 557.29 (344.89) 511.52 (280.31) 0.56 CD8, cells/μL 273.85 (213.90) 212.77 (113.26) 0.15 NK, cells/μL, median (IQR) 31.00 (19.50-64.25) 46.50 (28.25-80.75) 0.08 B1 (cells/μL) 63.65 (74.71) 46.97 (64.53) 0.35 B2 (cells/μL) 248.85 (180.29) 244.76 (32.65) 0.94 ALT, U/L, median (IQR) 48.0 (25.5-92.0) 67.0 (38.0-157.5) 0.06 AST, U/L, median (IQR) 45.0 (22.0-107.5) 132.0 (38.5-271.0) 0.02* CK, U/L, median (IQR) 233.0 (95.5-1685.0) 1462.0 (177.0-6163.0) 0.01* LDH, U/L, mean (SD) 383.65 (238.32) 590.73 (370.32) 0.006** Albumin, g/L, mean (SD) 36.69 (5.29) 33.19 (7.23) 0.02* Prealbumin, mg/L, mean (SD) 220.10 (98.05) 182.72 (74.67) 0.08 C3, mg/dL, mean (SD) 75.24 (25.79) 86.32 (17.93) 0.04* C4, mg/dL, mean (SD) 16.94 (6.43) 20.16 (4.95) 0.02* CRP, mg/dL, median (IQR) 0.44 (0.19-0.94) 0.63 (0.39-1.27) 0.12 ESR, mm/h, median (IQR) 11.0 (7.0-21.5) 16.0 (8.0-33.0) 0.16 Serum ferritin, ng/mL, median (IQR) 139.2 (54.0-606.0) 312.9 (145.4-768.5) 0.01* ANA positive 13 (35) 17 (52) 0.17 Cancer-associated myositis 1 (3) 3 (12) 0.34b Muscle biopsy 30 (81) 25 (76) 0.59 Data are in n (%) unless otherwise indicated.
↵aAll WBC values are reported as mean (SD), except for NK, which is reported as median (IQR).
↵bThese data were deleted because patients were lost to follow-up.
↵*P < 0.05.
↵**P < 0.01. ALT: alanine aminotransferase; ANA: antinuclear antibody; AST: aspartate aminotransferase; CK: creatine kinase; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase ; NK: natural killer; WBC: white blood cell.
